Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 126-135 of 135
< Previous 1 ... 4 5 6

  • Technetium Tc-99m Sestamibi SPECT / CT Imaging in Treating Patients with Kidney Cancer

    This phase I trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography (SPECT) / computed tomography (CT) imaging works in treating patients with kidney cancer. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT / CT, may help find and diagnose kidney cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Radiosurgery in Treating Patients with Stage I Kidney Cancer

    This phase II trial studies how well radiosurgery works in treating patients with stage I kidney cancer. Radiosurgery can send large doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts

  • Mithramycin for Lung, Esophagus, and Other Chest Cancers

    Background: - Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment. Research suggests that it may be useful against some cancers of the chest, such as lung and esophageal cancer or mesothelioma. Researchers want to see if mithramycin can be used to treat these types of cancer. Objectives: - To see if mithramycin is safe and effective against different chest cancers. Eligibility: - Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum cancers. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and tumor tissue samples will be used to monitor the cancer before treatment. - Participants will receive mithramycin every day for 7 days, followed by 7 days without treatment. Each 14-day round of treatment is called a cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will continue to take the drug for as long as the side effects are not severe and the tumor responds to treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

    This is a Phase 1b / 2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the PARP inhibitor talazoparib in participants with advanced / metastatic solid tumors.
    Location: 2 locations

  • Trigriluzole with Nivolumab and Pembrolizumab in Treating Patients with Metastatic or Unresectable Solid Malignancies or Lymphoma

    This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or cannot be removed by surgery. Trigriluzole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving trigriluzole in combination with nivolumab and pembrolizumab may work better at treating patients with solid malignancies or lymphoma.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

    This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD / RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.
    Location: 3 locations

  • CBM588, Nivolumab, and Ipilimumab in Treating Patients with Stage IV or Advanced Kidney Cancer

    This phase I trial studies how well CBM588 works when given together with nivolumab and ipilimumab in treating patients with kidney cancer that is stage IV or has spread to other places in the body. CBM588 is a probiotic that may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CBM588, nivolumab, and ipilimumab may work better in treating patients with kidney cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Enzalutamide before Surgery in Treating Patients with Kidney Cancer

    This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Aldesleukin and Pembrolizumab in Treating Participants with Stage III and IV Melanoma and Renal Cell Cancer

    This phase I / II trial studies the side effects and how well pembrolizumab and aldesleukin work in treating participants with stage III and IV melanoma or renal cell cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Interleukins, such as aldesleukin, are proteins made by white blood cells and other cells in the body and may help regulate immune response. Giving pembrolizumab and aldesleukin may work better in treating melanoma and renal cell cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana


< Previous 1 ... 4 5 6